1 patient experienced grade 4 febrile neutropenia and septic shock, which resolved after withdrawal from the study, and no fatalities resulting from related AEs were seen. 1 . 1), and progression-free survival (PFS) were determined. == Results == Forty-six individuals were enrolled. Adverse occasions were generally mild ( grade 2), with diarrhea (44%), blurred vision (41%), nausea (37%), and fatigue (30%) becoming the most commonly observed treatment-related toxicities. Grade 3 fatigue and hypotension were reported in two patients each (4%). For all those evaluable individuals, the verified objective response rate was 26%, including one total and 11 partial responses, and the NVS-CRF38 median PFS was 4. 8 months. The median duration of response was 19. 1 weeks. Notably, NVS-CRF38 in the subset of patients who had received three or fewer prior lines of therapy (n = 23), an objective response price of 39%, PFS of 6. 7 months, and duration of response of 19. 6 weeks were seen. == Bottom line == IMGN853 exhibited a manageable security profile and was energetic in platinum-resistant ovarian cancer, with the strongest signals of efficacy observed in less heavily pretreated individuals. On the basis of these findings, the dose, routine, and target population were identified for any phase III trial of IMGN853 monotherapy in individuals with platinum-resistant disease. == INTRODUCTION == The American Cancer Culture estimates that 22, 280 women in the United States will be diagnosed with epithelial ovarian cancer (EOC) in 2016, and 14, 240 will certainly die because of this disease. 1EOC, overwhelmingly diagnosed at an advanced stage, is typically initially chemotherapy sensitive, and most individuals achieve remission with first-line platinum-based chemotherapy. Unfortunately, up to 80% of those women will certainly relapse and require further treatment without the expectation of cure. 2Recurrent EOC is usually classified based on the length of time since receiving treatment with a platinum agent. Relapsed disease within 6 months of completing initial platinum therapy is classified because primary platinum resistant. Relapsed disease past 6 months is usually classified because platinum sensitive, and these patients possess a high likelihood of responding to additional platinum-based therapy. However , just about all platinum-sensitive individuals will ultimately develop resistance, at which point they are considered to possess acquired secondary platinum resistance. 3-6Both main and attained resistance to platinum impart a highly negative prognosis for individuals with EOC, and active agents for this populace represent an urgent unmet clinical need. Folate receptor alpha (FR) is a cell-surface transmembrane glycoprotein that facilitates the unidirectional transportation of folates into cells. 7This receptor shows a restricted distribution pattern in regular tissues, with expression limited to a variety of polarized epithelia, such as those found in the choroid plexus, kidney, uterus, ovary, lung, and placenta. 7, 8In contrast, aberrant FR overexpression is usually characteristic of a number of epithelial tumors, including ovarian, endometrial, and nonsmall-cell lung cancers. 9In EOC specifically, approximately 80% of tumors constitutively express FR10; moreover, raised receptor manifestation may be a negative prognostic element with respect to chemotherapeutic response in this malignancy. 11Thus, FR offers emerged because an attractive candidate for molecularly targeted therapeutic approaches, particularly in EOC. 9, 12, 13 Early approaches to focusing on the folate receptor evaluated small-molecule folatecytotoxic agent conjugates (BMS-748285, vintafolide) and a nonconjugated humanized antibody (farletuzumab), 9, 14, 15but with disappointing clinical activity. The differential manifestation of FR and its ability to internalize large molecules make this receptor well suited for antibodydrug NVS-CRF38 conjugate (ADC) centered strategies that may couple the targeting and pharmacokinetic top features of an antibody with the cancer-killing impact of a cytotoxic agent. In this regard, mirvetuximab soravtansine (IMGN853) is an ADC comprising a humanized FR-binding monoclonal antibody conjugated to the cytotoxic maytansinoid effector molecule DM4. 15, 16IMGN853 binds with high affinity and specificity to FR on the surface of tumor cells, which, upon antigen binding, encourages ADC internalization and intracellular release of DM4. 17DM4 subsequently acts as an antimitotic agent to inhibit tubulin polymerization and disrupt microtubule assembly, resulting in cell-cycle arrest and apoptosis. 18In addition, the cleavable linker design of IMGN853 allows active DM4 metabolites to diffuse into proximal tumor cells and kill them, an effect known as bystander eliminating. 19In preclinical studies, IMGN853 has shown strong antitumor activity in FR-positive tumors, including in models Fshr of EOC. 20The primary objective of our research was to evaluate the safety and clinical activity of mirvetuximab soravtansine in individuals with FR-positive and platinum-resistant EOC, fallopian tube cancer, or main peritoneal cancer. == INDIVIDUALS AND METHODS == == Eligibility Criteria == Adults with histologically confirmed EOC, primary peritoneal cancer, or fallopian tube cancer who had experienced progression NVS-CRF38 or relapse within 6 months of completing prior platinum-based therapy were eligible to enroll in the platinum-resistant expansion cohort. Patients had to have met the minimum requirement of FR positivity on archival tumor examples by immunohistochemistry (IHC; 25% of tumor staining at 2+ intensity). Tumor cells.